We are delighted to announce that Biointron will be participating in the Biologics USA 2024 conference, taking place from October 3 to 4, 2024, in San Diego, California. This event is a premier gathering for the biologics sector, providing a unique platform for industry leaders, researchers, and professionals to discuss the latest advancements and trends in biologics.
We are delighted to announce that Biointron will be participating in the 15th Annual World Bispecific Summit, scheduled to take place from September 3 to 5, 2024, in Boston, Massachusetts. This summit is a cornerstone event for the bispecific antibody community, attracting thought leaders and industry experts worldwide to discuss the latest innovations and breakthroughs in bispecific therapeutics.
We are excited to announce that Biointron will be participating in the upcoming BIO Asia - Taiwan Conference, set to take place from July 24 to 28, 2024, at the Taipei Nangang Exhibition Center. This prestigious event is a major gathering for the biotechnology and pharmaceutical industries, attracting professionals and companies from around the globe.
We are pleased to announce that Biointron will be attending the Next-gen Immuno-Oncology Conference 2024, scheduled for June 20-21, 2024, in Boston, Massachusetts. This distinguished event, organized by MarketsandMarkets, brings together leading experts, researchers, and industry professionals to discuss the latest advancements and trends in immuno-oncology.
Antibody drugs in ophthalmology represent a significant advancement in treating various eye diseases. These biologics target specific proteins involved in pathological processes, such as vascular endothelial growth factor (VEGF), which plays a key role in conditions like age-related macular degenera
BIO 2024 in San Diego showcased biotech innovation. Biointron reports highlights on antibody discovery, engineering, and collaborations shaping the future of biologics.
Antibody-antibiotic conjugates fight resistant bacteria with precision. Biointron highlights how AACs combine antibody targeting with antibiotic power for infections.
Ozempic, a brand name for the drug semaglutide, was originally developed to manage type 2 diabetes by improving blood sugar control. As a GLP-1 receptor agonist, it mimics a hormone that regulates glucose metabolism and appetite. Beyond its success in diabetes treatment, Ozempic has garnered signifi
We are delighted to announce that Biointron will be attending the Antibody Therapeutics Xchange 2024 Boston, which will take place on June 17, 2024. This exclusive event is a gathering of the leading minds in antibody therapeutics, offering a unique platform for collaboration, innovation, and knowledge sharing.
MAGMA-seq is an integrated technology for antibody wide mutational scanning. DOI:10.1038/s41467-024-48072-zThe use of bioinformatics and computational methods were of high interest in several papers published this past week. Protein language models, akin to natural language processing tools, p
Discover highlights from CAS 2024, featuring advances in cancer immunotherapy, Alzheimer’s research, protein bioinformatics, and antibody engineering breakthroughs.
Antibody drugs for diabetes typically target specific molecules involved in the regulation of blood sugar levels or the immune response against insulin-producing cells, or specific hormones or receptors involved in glucose metabolism. For instance, teplizumab (Tzield), targets CD3 on T cells, thus deactivating immune cells which attack β-cells.
Analytical tools define antibody quality. Biointron applies SPR, BLI, and mass spectrometry to deliver precise characterization and support therapeutic success.
This month heralded the release of groundbreaking news involving the monoclonal antibody tegoprubart, which facilitated the successful transplantation of a genetically edited pig kidney into a 62-year-old man grappling with end-stage kidney disease.
In March 2024, Cyagen and Biointron officially signed off on their strategic partnership, forging an alliance in antibody drug development. This partnership aims to fully leverage the strengths of Cyagen's HUGO-Ab™ fully humanized mouse antibody discovery platform and Biointron&#
You can also contact us on the Scientist and Science Exchange marketplaces.
